Recital 4, Regulation (EU) 2026/977

In forcesince 4 May 2026

The individual practices that notified bodies apply as regards quality management and procedural requirements diverge significantly, thus putting manufacturers in unequal positions across the internal market. This is particularly relevant in case of manufacturers that are small and medium-sized enterprises. Such practices have an impact on the predictability and on the timely completion of conformity assessment activities, with significant repercussions and delays for innovation and the health of patients.